Determining the cost-effectiveness of endoscopic surveillance for gastric cancer in patients with precancerous lesions

Asia-Pacific Journal of Clinical Oncology

Volumn 12, Issue 4, 2016, Pages 359-368

  Wu, Jin Tong ^a   Zhou, Jun ^a   Naidoo, Nasheen ^b   Yang, Wen Yu ^a   Lin, Xiao Cheng ^a   Wang, Pei ^c   Ding, Jin Qin ^a   Wu, Chen Bin ^a   Zhou, Hui Jun ^d  

^a FUZHOU GENERAL HOSPITAL   (China)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL HEALTHCARE GROUP   (Singapore)

Author keywords

cost benefit analysis; early detection of cancer; gastrointestinal endoscopy; Markov chains; stomach neoplasm

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HIDDEN MARKOV MODEL; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRECANCER; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SINGAPOREAN; STOMACH CANCER; UNCERTAINTY; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ENDOSCOPY; PATHOLOGY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; STOMACH TUMOR;

AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; ENDOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; STOMACH NEOPLASMS;

EID: 84994388363     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12569     Document Type: Article

References (50)

1. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006; 118: 2315–21.
2. Lee YC, Lin JT, Wu HM et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 875–85.
3. Babazono A, Hillman AL. Declining cost-effectiveness of screening for disease. The case of gastric cancer in Japan. Int J Technol Assess Health Care 1995; 11: 354–64.
4. Fock KM, Talley N, Moayyedi P et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351–65.
5. Dinis-Ribeiro M, Areia M, de Vries AC et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74–94.
6. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Moreira-Dias L. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 2007; 22: 1594–604.
7. Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2004; 2: 868–79.
8. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006; 4: 709–16.
9. Zhou HJ, Li SC, Naidoo N, Zhu F, Yeoh KG. Empirical evidence of the continuing improvement in cost efficiency of an endoscopic surveillance programme for gastric cancer in Singapore from 2004 to 2010. BMC Health Serv Res 2013; 13: 139.
10. Zhu F, Loh M, Hill J et al. Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: a cohort study. BMC Gastroenterol 2009; 9: 76.
11. Singapore Cancer Registry Committee. Trends in cancer incidence in Singapore 1968-2007. Singapore Cancer Registry Report. Singapore 2012; 191.
12. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol 2010; 45: 1–8.
13. El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 2001; 54: 679–83.
14. Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. J Clin Gastroenterol 2003; 36: S29-36; discussion S61–2.
15. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50: 378–81.
16. Tsubono Y, Nishino Y, Tsuji I, Hisamichi S. Screening for gastric cancer in Miyagi, Japan: evaluation with a population-based cancer registry. Asian Pac J Cancer Prev 2000; 1: 57–60.
17. Wong BC, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187–94.
18. Department of Statistics Singapore. Yearbook of Statistics Singapore 2012. 45 ed. Singapore Ministry of Trade & Industry, Republic of Singapore, 2012.
19. U.S. Environmental Protection Agency. Cost of Illness Hand book Pennsylvania US Environmental Protection Agency, 2010.
20. Watabe H, Mitsushima T, Yamaji Y et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764–8.
21. Ang TL, Fock KM, Dhamodaran S, Teo EK, Tan J. Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population. J Gastroenterol Hepatol 2005; 20: 1603–9.
22. Centers for Disease Control and Prevention NBCCEDP. Policies and Procedures manual. Atlanta: Centers Disease Control & Prevention, 2005.
23. Subramanian S, Tangka FKL, Hoover S, DeGroff A, Royalty J, Seeff LC. Clinical and programmatic costs of implementing colorectal cancer screening: evaluation of five programs. Eval Program Planning 2011; 34: 147–53.
24. Environmental Protection Agency USA. Cost of stomach cancer. Cost of Illness Handbook. Environmental Protection Agency USA, Washington DC 2000; 1–45.
25. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253–8.
26. Kim YS, Park HA, Kim BS, Yook JH, Lee MS. Efficacy of screening for gastric cancer in a Korean adult population: a case-control study. J Korean Med Sci 2000; 15: 510–5.
27. Matsumoto S, Yamasaki K, Tsuji K, Shirahama S. Results of mass endoscopic examination for gastric cancer in Kamigoto Hospital, Nagasaki Prefecture. World J Gastroenterol 2007; 13: 4316–20.
28. Voutilainen ME, Juhola MT. Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy. Eur J Gastroenterol Hepatol 2005; 17: 1345–9.
29. Zhou HJ, So JB, Yong WP et al. Validation of the functional assessment of cancer therapy – gastric module for the Chinese population. Health Qual Life Outcomes 2012; 10: 145.
30. Munene G, Francis W, Garland SN, Pelletier G, Mack LA, Bathe OF. The quality of life trajectory of resected gastric cancer. J Surg Oncol 2012; 105: 337–41.
31. Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development. World Health Organization, Geneva 2001.
32. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197–200.
33. Chang HS, Park EC, Chung W, Nam CM, Choi KS, Cho E, Cho WH. Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis. Asian Pac J Cancer Prev 2012; 13: 2721–8.
34. Leung WK, Wu MS, Kakugawa Y et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9: 279–87.
35. Chien PF, Khan KS. Evaluation of a clinical test. II: Assessment of validity. BJOG 2001; 108: 568–72.
36. Mansley EC, Dunet DO, May DS, Chattopadhyay SK, McKenna MT. Variation in average costs among federally sponsored state-organized cancer detection programs: economies of scale? Med Decis Making 2002; 22: S67–79.
37. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735–40.
38. Hirota WK, Zuckerman MJ, Adler DG et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63: 570–80.
39. Rugge M, Cassaro M, Di Mario F et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003; 52: 1111–6.
40. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–9.
41. Vannella L, Lahner E, Osborn J, Bordi C, Miglione M, Delle Fave G, Annibale B. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 2010; 31: 1042–50.
42. Huang JQ, Hunt RH. The evolving epidemiology of Helicobacter pylori infection and gastric cancer. Can J Gastroenterol 2003; 17 (Suppl B): 18B–20B.
43. Zagari RM, Romano M, Ojetti V et al. Guidelines for the management of Helicobacter pylori infection in Italy: the III Working Group Consensus Report 2015. Digest Liver Disease 2015; 47: 903–12.
44. Weinstein MC, O'Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 2003; 6: 9–17.
45. Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol 2007; 25: 203–8.
46. Choi KS, Kwak MS, Lee HY, Jun JK, Hahm MI, Park EC. Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series. Cancer Epidemiol Biomarkers Prev 2009; 18: 1390–8.
47. Koong HN, Chan HS, Nambiar R, Soo KC, Ho J, Ng HS, Ng EH. Gastric cancers in Singapore: poor prognosis arising from late presentation. Aust N Z J Surg 1996; 66: 813–5.
48. Wai CT, Yeoh KG, Ho KY, Kang JY, Lim SG. Diagnostic yield of upper endoscopy in Asian patients presenting with dyspepsia. Gastrointest Endosc 2002; 56: 548–51.
49. Kubota H, Kotoh T, Masunaga R et al. Impact of screening survey of gastric cancer on clinicopathological features and survival: retrospective study at a single institution. Surgery 2000; 128: 41–7.
50. Nakashima H, Nagahama R, Yamamoto T, Ohkura Y. Mass screening for gastric cancer: how to select patients for endoscopic examination. Gastric Cancer 2010; 13: 78–83.